172 related articles for article (PubMed ID: 24733693)
1. INDs for PET molecular imaging probes-approach by an academic institution.
Mosessian S; Duarte-Vogel SM; Stout DB; Roos KP; Lawson GW; Jordan MC; Ogden A; Matter C; Sadeghi S; Mills GQ; Schelbert HR; Radu CG; Czernin J; Couto M; Phelps ME
Mol Imaging Biol; 2014 Aug; 16(4):441-8. PubMed ID: 24733693
[TBL] [Abstract][Full Text] [Related]
2. A rational regulatory approach for positron emission tomography imaging probes: from "first in man" to NDA approval and reimbursement.
Barrio JR; Marcus CS; Hung JC; Keppler JS
Mol Imaging Biol; 2004; 6(6):361-7. PubMed ID: 15564146
[TBL] [Abstract][Full Text] [Related]
3. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
Harapanhalli RS
Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
[TBL] [Abstract][Full Text] [Related]
4. An Analysis of Antibacterial Drug Development Trends in the United States, 1980-2019.
Dheman N; Mahoney N; Cox EM; Farley JJ; Amini T; Lanthier ML
Clin Infect Dis; 2021 Dec; 73(11):e4444-e4450. PubMed ID: 32584952
[TBL] [Abstract][Full Text] [Related]
5. An FDA analysis of clinical hold deficiencies affecting investigational new drug applications for oncology products.
Manning ML; Thompson MD; Saber H; Maher VE; Crich JZ; Leighton JK
Regul Toxicol Pharmacol; 2020 Feb; 110():104511. PubMed ID: 31678263
[TBL] [Abstract][Full Text] [Related]
6. Regulatory Agencies and PET/CT Imaging in the Clinic.
Herscovitch P
Curr Cardiol Rep; 2022 Oct; 24(10):1361-1371. PubMed ID: 35913674
[TBL] [Abstract][Full Text] [Related]
7. Investigational New Drug applications: a 1-year pilot study on rates and reasons for clinical hold.
Lapteva L; Pariser AR
J Investig Med; 2016 Feb; 64(2):376-82. PubMed ID: 26911627
[TBL] [Abstract][Full Text] [Related]
8. Bringing New PET drugs to clinical practice - a regulatory perspective.
Hung JC
Theranostics; 2013 Nov; 3(11):885-93. PubMed ID: 24312157
[TBL] [Abstract][Full Text] [Related]
9. The investigator-sponsored IND in clinical trials.
Haakenson C; Fye CL; Sather MR; Toussaint DJ
Control Clin Trials; 1987 Jun; 8(2):101-9. PubMed ID: 3608504
[TBL] [Abstract][Full Text] [Related]
10. Translating a radiolabeled imaging agent to the clinic.
Griffiths GL; Vasquez C; Escorcia F; Clanton J; Lindenberg L; Mena E; Choyke PL
Adv Drug Deliv Rev; 2022 Feb; 181():114086. PubMed ID: 34942275
[TBL] [Abstract][Full Text] [Related]
11. Proceedings: PET Drugs-A Workshop on Inspections Management and Regulatory Considerations.
Bunning S; Ignace C; Mattmuller S; Schwarz SW; Scott PJH; VanBrocklin HF; Zigler SS;
J Nucl Med; 2022 Jul; 63(7):1117-1123. PubMed ID: 35058318
[TBL] [Abstract][Full Text] [Related]
12. PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications.
Karara AH; Edeki T; McLeod J; Tonelli AP; Wagner JA
J Clin Pharmacol; 2010 Apr; 50(4):380-91. PubMed ID: 20097935
[TBL] [Abstract][Full Text] [Related]
13. Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation?
Holbein ME; Berglund JP; Weatherwax K; Gerber DE; Adamo JE
Clin Transl Sci; 2015 Oct; 8(5):526-32. PubMed ID: 25588691
[TBL] [Abstract][Full Text] [Related]
14. [Molecular imaging-based early-phase and exploratory clinical research].
Watanabe Y
Yakugaku Zasshi; 2013; 133(2):187-95. PubMed ID: 23370512
[TBL] [Abstract][Full Text] [Related]
15. The Majority of Expedited Investigational New Drug Safety Reports Are Uninformative.
Jarow JP; Casak S; Chuk M; Ehrlich LA; Khozin S
Clin Cancer Res; 2016 May; 22(9):2111-3. PubMed ID: 26783289
[TBL] [Abstract][Full Text] [Related]
16. Regulatory Requirements for PET Drug Production.
Schwarz SW; Dick D; VanBrocklin HF; Hoffman JM
J Nucl Med; 2014 Jul; 55(7):1132-7. PubMed ID: 24914057
[TBL] [Abstract][Full Text] [Related]
17. Clinical studies involving probiotics: when FDA's investigational new drug rubric applies-and when it may not.
Degnan FH
Gut Microbes; 2012; 3(6):485-9. PubMed ID: 23060015
[TBL] [Abstract][Full Text] [Related]
18. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
19. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
[TBL] [Abstract][Full Text] [Related]
20. The radioactive drug research committee: Background and retrospective study of reported research data (1975-2004).
Suleiman OH; Fejka R; Houn F; Walsh M
J Nucl Med; 2006 Jul; 47(7):1220-6. PubMed ID: 16818959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
